Trial Profile
A Phase I Trial of Regorafenib and Cetuximab in Patients With Advanced Malignancy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Regorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Apr 2020 Status changed from active, no longer recruiting to completed.
- 24 May 2019 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.